Skip to main content

Table 6 Description of the 14 children with virological failure (HIV RNA >1000 copies/mL) after the switch

From: Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d’Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial

Number Country Arm HIV-1 subtype Exposure to prenatal ART, maternal or child PMTCT or postnatal ART via breast milk HIV RNA at ART initiation (copies/mL) Mutations at ART initiation   HIV RNA at 12- month post-randomisation (copies/mL) Mutations at failure post-switch
       NRTI NNRTI PI   NRTI NNRTI PI
1 BF EFV CRF02_AG No exposure 19,900,000 None None None 6109 None K103N None
2 CI EFV CRF02_AG Exposure to child PMTCT (AZT + sdNVP) and postnatal maternal ART (AZT + 3TC + NVP) 242,757 M184V K103N None 2091 M184V K103N, H221Y None
3 CI EFV CRF02_AG Exposure to maternal PMTCT (AZT) and to child PMTCT (AZT+ sdNVP) 3,573,953 None None None 62,866 None None None
4 CI EFV CRF02_AG No exposure 1,321,600 None None None 102,417 M184V K103N None
5 CI EFV CRF02_AG Exposure to maternal PMTCT (AZT + 3TC + NVP) and to child PMTCT (AZT + sdNVP) 3,459,135 None None None 1564 Not amplified Not amplified Not amplified
6 CI EFV CRF02_AG Exposure to postnatal maternal ART (AZT + 3TC + NVP) 608,578 None V90I, V179I None 21,397 M184V V90I, V179I, K103N None
7 CI EFV CRF02_AG Exposure to prenatal maternal ART (AZT + 3TC + NVP) initiated 7 years before delivery 12,466,057 M41L, V108I, M184V, L210W, T215Y Y181C, P225H None 61,199 M41L, V108I, M184V, L210W, T215Y, L74I K101E, Y181C, P225H None
8 BF LPV/r CRF02_AG Exposure to maternal PMTCT (AZT) 7,780,000 None None None 7,920,000 None None None
9 BF LPV/r URF-GK Exposure to maternal PMTCT (AZT+3TC+NVP) and to child PMTCT (sdNVP) and to postnatal maternal ART (TDF + 3TC + NVP) 4,720,000 None K103N None 261,914 None K103N, Y181C None
10 BF LPV/r CRF02_AG Exposure to maternal PMTCT (AZT + 3TC + NVP) and child PMTCT (sdNVP) 56,600,000 None Y181C None 25,054 None Y181C None
11 CI LPV/r CRF02_AG Exposure to child PMTCT (AZT + sdNVP) 254,456 None None None 2603 None None None
12 CI LPV/r CRF02_AG No exposure 451,590 None None None 67,342 M184V None None
13 CI LPV/r CRF02_CPX No exposure 915,685 None K103N, V90I, K101EK None 3,879,063 None K103N, V90I, K101EK None
14 CI LPV/r CRF02_AG Exposure to maternal PMTCT (unknown) and to postnatal maternal ART (AZT + 3TC + LPV/r) 2,710,000 None None None 1848 M184V K103N None
  1. ART, Antiretroviral therapy, PMTCT Prevention of mother-to-child-transmission, NRTI Nucleoside reverse transcriptase inhibitor, NNRTI Non-nucleoside reverse transcriptase inhibitor, PI Protease inhibitor, BF Burkina Faso, CI Cote d’Ivoire, EFV Efavirenz, LPV/r Lopinavir-boosted ritonavir, AZT Zidovudine, sdNVP single-dose nevirapine, 3TC Lamivudine, NVP Nevirapine, TDF